Introduction
Since their introduction about a decade ago, tumour necrosis factor (TNF) alpha antagonist drugs have greatly improved the clinical management of autoimmune disorders and are now widely used in rheumatology. The flipside of the coin is an increase in infectious disease risk in patients treated with these drugs. Both reactivation of latent infections and increased susceptibility to new infections have been observed in patients receiving TNF alpha antagonist therapy. Depending on their mode of action, the TNF alpha antagonist drugs most widely used can be distinguished in two major groups: monoclonal antibodies, such as infliximab and adalimumab, and the receptor construct etanercept [1] .
Leishmaniasis is endemic in large parts of southern Europe [2] [3] [4] [5] where studies suggest a focal prevalence of latent infection of up to 53% in the adult population [5] . Two species, Leishmania infantum and L. tropica are transmitted around the Mediterranean basin by the bite of sandfly species (order Diptera, family Psychodidae, subfamily Phlebotominae) [4] . The spectrum of manifest infection ranges from a well localised, self-healing cutaneous papule or ulceration to rapidly fatal visceral disease. Host immunity is known to be a key determinant of the clinical manifestation and outcome. Immuno¬suppression, in particular conditions that alter the type 1 helper T-cell-mediated immune response of which TNF alpha is an important component, is generally regarded as a risk factor for manifest leishmaniasis and has been identified as a major contributor to its re-emergence in Europe [4] . A number of published case reports suggest an association of TNF alpha antagonist use and manifest leishmaniasis [6, 7] . Despite this, no systematic research on opportunistic leishmaniasis in patients receiving TNF alpha antagonists has been conducted.
Based on a brief summary of published information on opportunistic leishmaniasis and use of TNF alpha antagonists, this perspective identifies areas of uncertainty regarding their safety profile and their clinical use in patients at risk of leishmaniasis. We then reflect on how current pharmacovigilance activities in Europe could be enhanced to help reduce these uncertainties. Our aim is to stimulate a debate about this important drug safety issue with potential consequences for patients receiving TNF alpha antagonists living in or travelling to areas endemic for leishmaniasis.
Current knowledge on tumor necrosis factor alpha antagonist therapy and leishmaniasis
Published research on therapy with TNF alpha antagonists and leishmaniasis is scarce and limited to case reports and case series. We recently reviewed the literature [6] and identified 19 descriptions of patients with leishmaniasis while receiving TNF antagonists, published between 2004 and 2011. Nearly all of the identified cases (18/19) occurred in Europe, and more than two thirds were published in 2010-11. The vast majority were reported from endemic regions of southern Europe (14/18) whereas fewer occurred after travel to and migration from endemic areas (4/18). The reported time period from initiation of treatment to onset of leishmaniasis ranged from 0.5 to 48 months, consistent with both reactivation of latent infection and increased susceptibility to new infection.
Only one reported case was treated with etanercept while all others received either infliximab or adalimumab. This was surprising, since prescription data from the countries where the cases occurred showed that each of the three drugs was prescribed about equally often. These findings suggest that opportunistic leishmaniasis is more likely to occur in patients receiving TNF alpha monoclonal antibodies than in patients treated with etanercept. This interpretation is supported by similar findings for tuberculosis [8, 9] and by studies in mice [10] and in vitro [11] .
Interestingly, published case reports describe various approaches including discontinuation as well as continuation of TNF alpha antagonist therapy during and after anti-parasitic treatment while using the same or a different type of drug for ongoing TNF alpha antagonisation [6] . Their number, however, is too small and the data and observation period reported too heterogeneous to decide whether one or the other approach is associated with an increased risk of recurrent leishmaniasis.
Although it provided us with a hypothesis on the possible differences of leishmaniasis risk by type of TNF alpha antagonist used, our analysis of case reports is limited by potential publication bias and confounding underlying the observed associations. Moreover, the number of published cases is likely to represent only a small fraction of patients treated with TNF alpha antagonists with opportunistic leishmaniasis, leaving the magnitude of this drug safety issue unclear. Hence more systematic research is needed to improve our
Box 1
Aims and objectives of a coordinated research effort on opportunistic leishmaniasis in patients treated with tumor necrosis factor alpha antagonists in Europe
Aims
• Estimate the impact of TNF alpha use on the occurrence of leishmaniasis in Europe.
• Reduce leishmaniasis risk by tailoring TNF alpha antagonist therapy to individual risk profile.
• Optimise anti-parasitic and anti-rheumatic therapy in patients with opportunistic leishmaniasis.
Objectives
• Define the absolute risk of leishmaniasis in patients treated with TNF alpha antagonists. Define the relative risk of leishmaniasis in patients treated with TNF alpha antagonists with respect to classic immunosuppressive regimens; and with respect to type of TNF alpha antagonist used.
• Define the proportionate contribution of new infection and reactivation towards the burden of leishmaniasis in patients treated with TNF alpha antagonists overall; and by type of TNF alpha antagonist used.
• Define the role of screening (serology, intradermal leishmanin) in patients treated with TNF alpha antagonists for clinical decision making by determining their predictive values with regard to the overall risk of leishmaniasis; and depending on the type of TNF alpha antagonist used.
• Identify groups at risk of and factors associated with developing leishmaniasis during TNF alpha antagonist therapy namely environmental/behavioural (e.g. companion animals, travel, region of residence) factors; host factors (e.g. co-morbidity); and others (e.g. immunosuppressive co-medication).
• Optimise therapy of leishmaniasis as complication of TNF alpha therapy through either interruption or continuation of TNF alpha antagonist; and systemic or local treatment of cutaneous leishmaniasis.
• Explore whether TNF alpha antagonists can be restarted after cure of leishmaniasis and if there is a need for potential modifications of this therapy; treatment can be continued with identical or alternative TNF alpha antagonist; immunosuppressive co-medication needs to be modified; and anti-parasitic maintenance therapy is necessary to prevent relapses (secondary prevention).
TNF: tumor necrosis factor.
understanding of opportunistic leishmaniasis in these patients.
Unsolved questions
The main areas of uncertainty pertaining to opportunistic leishmaniasis in patients receiving TNF alpha antagonist therapy, to be addressed by future research, are outlined below and summarised in Box 1.
There is a clear need to estimate the potential impact of TNF alpha antagonist use on the incidence of leishmaniasis. This information is required to clarify to what extent there is a need to further investigate and corroborate this association and to justify funding of research activities that aim at elucidating risk factors for leishmaniasis among those treated with TNF alpha antagonists.
Any study on risk factors should attempt to answer whether there truly is a difference in risk of leishmaniasis depending on the type of TNF alpha antagonist used. Once supported by evidence from prospective studies, physicians (mainly clinical rheumatologists) could directly translate this knowledge into practice by choosing the TNF alpha antagonist with the lowest risk for opportunistic leishmaniasis for patients living in or travelling to endemic areas. Moreover, the role of behavioural and host-associated risk factors for clinically manifest leishmaniasis under TNF alpha antagonist therapy should be evaluated as knowledge gained could be relevant in clinical decision-making or counselling of patients.
Once a risk difference for the various types of TNF alpha antagonists has been established, it will be important to clarify if this is due to reactivation of latent leishmaniasis or increased susceptibility to new infection.
It needs to be determined whether screening for latent infection before initiation of TNF alpha antagonist therapy can play a role in preventing opportunistic leishmaniasis. Studies evaluating the predictive values of serologic and intradermal leishmanin testing have great potential to inform clinical decision-making and will equally contribute to our understanding of latent versus newly acquired infection for the onset of opportunistic leishmaniasis in patients receiving anti-TNF alpha therapy.
Apart from defining risk factors, there is a need for clinical research to improve medical care for patients suffering from opportunistic leishmaniasis. In particular, better evidence on whether TNF alpha antagonists can be continued in patients with clinically active leishmaniasis, or after its cure, is of high clinical relevance since many of these patients depend on TNF alpha antagonists to adequately control the underlying autoimmune disease. Besides, future research has to address whether there is a need for secondary prevention of opportunistic leishmaniasis in patients that require sustained antagonisation of TNF alpha.
For instance, type and duration as well as indicators for the initiation of anti-parasitic maintenance therapy need to be established. Of note, anti-TNF alpha therapy has been continued or re-initiated in several cases of opportunistic leishmaniasis without subsequent relapse [6, 12] , indicating that a first episode does not justify long-term anti-parasitic treatment.
Finally, we have to learn more about the risk of generalised infection secondary to localised cutaneous leishmaniasis in patients receiving TNF alpha antagonists. Published case reports indicate that most clinicians fear this complication and opt for systemic anti-parasitic therapy. This, however, has to be balanced against increased toxicity when compared to local treatment which could be an option in a setting where close monitoring of the patient is ensured.
Research challenges concerning opportunistic leishmaniasis and tumor necrosis factor alpha antagonist therapy
Traditionally, spontaneous notification of adverse events to national pharmacovigilance systems has been used to define a drug's safety profile with regard to rare events and long-term effects that may have remained undetected during pre-licensure clinical trials. This approach, however, is subject to significant underreporting, does not allow analysing the number of reported events relative to the number of subjects treated, and cannot provide an estimate of the baseline risk.
In response to these shortcomings and with the support of the pharmaceutical industry, national rheumatology societies in several European countries have initiated national drug registers as post-marketing surveillance tools [13] . Many of these were put in place simultaneously to the licensing of the first TNF alpha antagonists about a decade ago. Their methodologies were recently reviewed in detail by Zink et al. [13] . In brief, selected care providers in rheumatology enrol patients receiving TNF alpha antagonists or other biotherapies into epidemiological cohort studies or into registers, thus overcoming some of the limitations of traditional pharmacovigilance activities.
Although a huge improvement compared to the traditional reporting systems, it has been called into question whether national drug registers cover a sufficient patient base to detect rare adverse events. Zink et al. estimate that events with an incidence equal or below one in 1,000 patient-years may not be adequately detected by this approach [13] . With regard to leishmaniasis, we observed that the French register only detected half of leishmaniasis cases reported in publications from France over a defined time period [6] , implying that underreporting may not be adequately addressed by the national registers. Besides, none of these registers had detected sufficient numbers of cases to allow analysing whether leishmaniasis risk varies by type of TNF alpha antagonist. As pointed out before, this was possible by combining published information from different European countries. Based hereon, it becomes obvious that fragmentation of data at national level hampers a better description of the safety profile of TNF alpha antagonists with regard to rare opportunistic infections. Therefore, evaluation of data across registers and at European level has been suggested to increase the ability to detect such events [13] . Although this approach has potential to contribute to our understanding of opportunistic leishmaniasis, a range of challenges remain.
Firstly, transmission of leishmaniasis occurs geographically in confined foci since it is bound to the presence of the phlebotomine vector. This is reflected in the large variation of sero-prevalence reported in regions around the Mediterranean basin [2, 3, 5] . Hence, to further advance our knowledge on opportunistic leishmaniasis in patients receiving biotherapies, it will be crucial that national drug registers adequately cover the population in areas where transmission occurs. The variation in transmission risk also implies that estimates of the absolute risk of leishmaniasis in TNF alpha antagonist users calculated from register data will vary according to the proportion of subjects live in endemic regions enrolled in the register.
Secondly, European national drug registers on the safety of TNF alpha antagonist drugs and other biotherapies use different methodology and do not record data in a uniform manner. To facilitate collaboration between national drug registers and to allow supranational data analyses, harmonisation of European registers is a prerequisite. A uniform reporting scheme has so far only been adopted by Great Britain, Sweden, and Germany, but not by France and Spain, countries where leishmaniasis is endemic [13] .
Thirdly, it is unclear, whether all countries with leishmaniasis endemic regions have an active national drug register or cohort. For instance, from a number of countries in the Balkan region, there are no peer-reviewed publications available on PubMed reporting on such activities.
The Table outlines potential components of a coordinated research effort on opportunistic leishmaniasis in Europe and Box 2 the resulting strengths.
Conclusions
Although the initiation of national registers with support of the pharmaceutical industry was a major step forward in better defining the safety profile of TNF alpha antagonist drugs and other biotherapies, there are shortcomings of this system with regard to opportunistic leishmaniasis. Crucial for improved case detection and reduced underreporting will be a closer link between existing national drug registers and institutions specialised in the diagnosis and therapy of leishmaniasis, e.g. tropical medicine institutes, dermatology departments, etc. This will likely enable the detection of a considerable number of additional cases of opportunistic leishmaniasis that are either directly seen at these institutions or were suspected elsewhere but laboratory confirmed there. Using existing network structures in Europe such as TropNet (www.tropnet.net) and EuroTravNet (www.istm.org/eurotravnet/ • Data on drug sales with sufficient detail allowing geographically high resolution in leishmaniasis endemic areas • Funding main.html) could facilitate the creation of such links. An extended network of clinical specialists in rheumatology, infectious diseases, tropical medicine, and dermatology will be necessary to answer the research questions pertaining to the clinical management of patients with opportunistic leishmaniasis set out in this paper.
Prospective data from a well-defined population at risk of acquiring or being latently infected with leishmania will be needed to obtain meaningful estimates of the incidence of clinical manifest infection that can be attributed to TNF alpha antagonist use and to evaluate the clinical role of screening for latent infection. This can only be achieved through focused post-marketing safety studies that make use of large cohorts in areas endemic for leishmaniasis. To ensure uniform methodology and data collection, such activity should be designed and coordinated at European level before being implemented by the existing national registers. In European countries endemic for leishmaniasis but without a well-functioning register or cohort, this may require enhancing or newly creating such structures. Taken together, these activities will need adequate funding and most importantly, substantial collaboration across disciplines including input from epidemiologists and public health experts.
